Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 122
- Registration Number
- NCT02582684
- Locations
- 🇺🇸
University of Southern California CRS (1201), Los Angeles, California, United States
🇺🇸UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States
The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 216
- Registration Number
- NCT02581202
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
Phase 2
Terminated
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02566707
- Locations
- 🇳🇱
St. Elisabeth, Tilburg, Netherlands
🇳🇱Rijstate, Arnhem, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients
Phase 4
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Peginterferon alfa-2a plus EntecavirDrug: Peginterferon alfa-2a plus LamivudineDrug: Peginterferon alfa-2a plus AdefovirDrug: Peginterferon alfa-2a plus Tenofovir
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 324
- Registration Number
- NCT02560649
A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
Phase 2
Completed
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 110
- Registration Number
- NCT02527096
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷Hôpital Saint-André, Bordeaux, France
🇫🇷Hôpital du Bocage, Dijon, France
Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02482272
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
Phase 4
- Conditions
- Patient ComplianceAntiretroviral Therapy Intolerance
- Interventions
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Juan A. Arnaiz
- Target Recruit Count
- 150
- Registration Number
- NCT02470650
- Locations
- 🇪🇸
Josep Mallolas Masferrer, Barcelona, Spain
Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial
Phase 4
Completed
- Conditions
- HIV
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 73
- Registration Number
- NCT02431975
- Locations
- 🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 734
- Registration Number
- NCT02403674
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
Phase 3
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitorDrug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitorDrug: Baseline regimen of two nucleoside reverse transcriptase inhibitors
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 673
- Registration Number
- NCT02397096
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath